SCHEMBL5541203

SCHEMBL5541203

Cc1ccc2c(c1)C(C)(C)C(=O)N2C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.39
CNR1 P21554 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
TP53 P04637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
POLB P06746 4/20 0.37
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
PGR P06401 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541199 0.82 MEN1 (0.33) KMT2AMEN1
SCHEMBL25491359 0.80 KMT2A (0.39) KMT2AMEN1KDM4EHTTMAPT
Bromide SCHEMBL6851490 0.79 PGR (0.42) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL5539734 0.77 MEN1 (0.56) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL5543415 0.77 CYP2C9 (0.49) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL16315802 0.76 TP53 (0.43) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL5541399 0.73 MEN1 (0.49) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL5544420 0.71 TP53 (0.44) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL7836213 0.70 TP53 (0.46) KMT2AMEN1KDM4EHTTMAPT
SCHEMBL16315828 0.69 POLB (0.63) KMT2AMEN1KDM4EHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885MEN1 3295/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.